Your browser doesn't support javascript.
loading
Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
Reichardt, P; Blay, J-Y; Gelderblom, H; Schlemmer, M; Demetri, G D; Bui-Nguyen, B; McArthur, G A; Yazji, S; Hsu, Y; Galetic, I; Rutkowski, P.
Affiliation
  • Reichardt P; HELIOS Klinikum Bad Saarow, Sarkomzentrum Berlin-Brandenburg, Bad Saarow, Germany. peter.reichardt@helios-kliniken.de
Ann Oncol ; 23(7): 1680-7, 2012 Jul.
Article in En | MEDLINE | ID: mdl-22357255
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyrimidines / Pyrroles / Gastrointestinal Stromal Tumors / Protein Kinase Inhibitors / Gastrointestinal Neoplasms / Indoles / Antineoplastic Agents Type of study: Clinical_trials Limits: Aged80 Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2012 Document type: Article Affiliation country: Germany
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperazines / Pyrimidines / Pyrroles / Gastrointestinal Stromal Tumors / Protein Kinase Inhibitors / Gastrointestinal Neoplasms / Indoles / Antineoplastic Agents Type of study: Clinical_trials Limits: Aged80 Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2012 Document type: Article Affiliation country: Germany